Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.25
Bid: 42.00
Ask: 42.50
Change: 0.25 (0.60%)
Spread: 0.50 (1.19%)
Open: 42.25
High: 42.25
Low: 42.25
Prev. Close: 42.00
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distribution Deals on Benecol 'once a day' Sachet

31 Mar 2016 07:00

RNS Number : 6206T
Venture Life Group PLC
31 March 2016
 

Venture Life Group PLC

 

("Venture Life" or the "Company")

 

First long term distribution deals on the new Benecol 'once a day' liquid sachet

 

Bracknell, UK - 31st March 2016: Venture Life Group PLC (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces that it has signed two long term distribution deals for its newly developed Benecol once-a-day liquid sachet. The active ingredient in the Benecol products, plant stanol ester, has been clinically proven to reduce LDL cholesterol. The sachet has been developed by Venture Life under Benecol licence from Raisio Group.

 

1. Turkey - long term agreement for the distribution of the Benecol once-a-day liquid sachet. The partner is a well-established company distributing into the pharmacy channel in Turkey. The sachet will require registering in Turkey, and will be launched in the market as soon as registration approval is granted.

2. Jordan - long term agreement for the distribution of both the Benecol once-a-day liquid sachet and the Benecol capsules. The capsules had previously been registered in Jordan by the Group's former distribution partner there and the consumer launch is now expected to take place during 2016, whilst the sachet progresses through the registration process.

 

Jerry Randall, Chief Executive Officer of Venture Life, commented: "I am delighted that we have concluded distribution agreements for our new Benecol once-a-day liquid sachet in these two important territories. We initially developed the Benecol capsules in 2014 and the successful development of our innovative liquid sachet format now gives our distribution partners the opportunity also to sell a once-a-day product that is expected to achieve better compliance with consumers. Like the capsules, the sachet has a two year shelf life and will be marketed through the pharmacy channel. The development of the sachet shows the ability of Venture Life to rapidly develop and bring to market innovative products that meet consumer needs. The Benecol products have been developed by Venture Life under licence from Raisio Group."

 

 

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer +44 (0)1344 742 870

James Hunter, Chief Financial Officer

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker) Freddy Crossley +44 (0) 20 7886 2500

Peter Steel

Duncan Monteith Corporate Finance

 

Tom SalvesenCorporate Broking

 

Square1 Consulting

David Bick +44 (0)20 7929 5599

Brian Alexander

 

About Venture Life

 

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

About Benecol

The Benecol® ingredient is the innovation of Raisio Group. Benecol products are available in some 30 countries. The efficacy and safety of the Benecol ingredient plant stanol ester has been verified in more than 70 published clinical trials. The sachet has been developed by Venture Life under licence from Raisio Group to develop and commercialise Benecol in certain forms of food supplement in certain territories. The capsules and sachet will be registered as food supplements.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRDMGFFNGFGVZM
Date   Source Headline
19th Apr 20247:00 amRNSRCF in Place and New Partner in the USA
9th Apr 20247:00 amRNSFinal Results for year ended 31 December 2023
4th Apr 20247:00 amRNSNotice of Results and Investor Presentation
19th Feb 20245:18 pmRNSHolding(s) in Company
6th Feb 202410:48 amRNSHolding(s) in Company
1st Feb 20247:00 amRNSTrading Update
20th Dec 20232:00 pmRNSHolding(s) in Company
28th Nov 202312:28 pmRNSHolding(s) in Company
22nd Nov 20234:05 pmRNSHolding(s) in Company
14th Nov 20237:00 amRNSChange of Nominated Adviser and Broker
31st Oct 20233:11 pmRNSHolding(s) in Company
17th Oct 20231:54 pmRNSHolding(s) in Company
25th Sep 20237:01 amRNSDirector/PDMR Shareholding
25th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSTrading Statement
5th Jul 20237:00 amRNSPDMR Shareholdings – Grant of Awards
26th Jun 20234:48 pmRNSDirector/PDMR Shareholding
25th May 20231:54 pmRNSDirector Dealings
22nd May 20233:01 pmRNSResults of AGM
22nd May 20237:00 amRNSAGM Statement
19th May 20237:00 amRNSBoard Change
9th May 20237:00 amRNSNotice of Capital Markets Event
28th Apr 202310:05 amRNSAnnual Report and Notice of AGM
5th Apr 20231:53 pmRNSDirector/PDMR Shareholding
4th Apr 20237:00 amRNSFinal Results for year ended 31 December 2022
31st Mar 20237:00 amRNSInvestor Presentation
13th Mar 20237:00 amRNSUpdate re Revolving Credit Facility
10th Mar 20232:05 pmRNSSecond Price Monitoring Extn
10th Mar 20232:00 pmRNSPrice Monitoring Extension
31st Jan 20237:00 amRNSTrading Statement
9th Jan 20237:00 amRNSLicensing and distribution agreements
1st Dec 20224:41 pmRNSSecond Price Monitoring Extn
1st Dec 20224:37 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSAcquisition and trading update
10th Oct 20227:00 amRNSDirectorate Changes
23rd Sep 202211:08 amRNSInvestor Presentation
22nd Sep 20227:00 amRNSHalf-year Report
25th Jul 202212:00 pmRNSDirector/PDMR Shareholding
25th Jul 20227:00 amRNSTrading Update
20th Jun 20222:31 pmRNSResults of AGM
10th Jun 202212:21 pmRNSDirector/PDMR Shareholding
9th Jun 20225:53 pmRNSAnnual Report & Notice of AGM - Correction
7th Jun 20227:00 amRNSAnnual Report & Notice of AGM
30th May 20224:22 pmRNSDirector/PDMR Shareholding
30th May 20227:00 amRNSDirectorate Changes
23rd May 20224:27 pmRNSHolding(s) in Company
20th May 20227:00 amRNSInvestor Presentation
17th May 20227:00 amRNSDirectorate Changes
17th May 20227:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.